What the FDA labels say about taking them together
Cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide and sucralfate
Cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide's FDA label of February 3, 2025 names sucralfate in its drug interactions section; the sucralfate labels PlainMeds reads (2) do not name cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide.
Check it at the source: the cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide FDA label on DailyMed (effective February 3, 2025, Gilead Sciences, Inc.); the sucralfate FDA label on DailyMed (effective September 2, 2026, Preferred Pharmaceuticals Inc.).
What does the cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide label say about sucralfate?
Cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide label, drug interactionsConcomitant Drug Class/Drug Name: Medications or Oral Supplements Containing Polyvalent Cations (e.g., Mg, Al, Ca, Fe, Zn): calcium or iron supplements, including multivitamins cation-containing antacids or laxatives sucralfate buffered medications; Effect on Concentration ↑ = Increase, ↓ = Decrease: ↓ elvitegravir; Clinical Comment: Separate GENVOYA and administration of medications, antacids, or oral supplements containing polyvalent cations by at least 2 hours.
Source: FDA drug label (Genvoya), Gilead Sciences, Inc., effective February 3, 2025 (SPL set 34784acf-15ed-4715-b504-eb30430518e9), via openFDA; the full label on DailyMed
What does the sucralfate label say about cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide?
Sucralfate's label (effective September 2, 2026) and its 1 other brand-application label do not name cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Sucralfate), NDA018333 (Abbvie), as published by Preferred Pharmaceuticals Inc., effective September 2, 2026 (SPL set 536b8c00-13ab-4397-a754-63a1c92bf883), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cobicistat, elvitegravir, emtricitabine and tenofovir alafenamide | Sucralfate | |
|---|---|---|
| Labeled for | HIV | Acid reflux and ulcers |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $143.35 per tablet Genvoya tablet | $0.173 per tablet 1 g tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once